Bruker vs Globus Medical
Add, change or remove companies; up to four.
The short version
- Bruker is the larger business, with $3.4B of revenue in fiscal 2025 against $2.9B for Globus Medical.
- Globus Medical grew revenue faster (16.7%, against 2.1%).
- Globus Medical kept more of each dollar of sales as operating profit (16.3% operating margin, against 2.0%).
- Globus Medical turned more of its sales into free cash flow (20.0% FCF margin, against 1.3%).
- Globus Medical earned a higher return on the capital invested in it (11.0%, against 0.9%).
| Latest fiscal year | BRKR · FY25 | GMED · FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.8B | $11.2B |
| Revenue | $3.4B | $2.9B |
| Free cash flow | $43.3M | $589M |
| Net income | −$8.6M | $538M |
| Growth | ||
| Revenue growth | 2.1% | 16.7% |
| 5-year growth | 11.6% | 30.1% |
| Share count change | 1.5% | −0.6% |
| Profitability | ||
| Gross margin | 45.9% | 67.4% |
| Operating margin | 2.0% | 16.3% |
| Net margin | −0.3% | 18.3% |
| FCF margin | 1.3% | 20.0% |
| Return on capital | 0.9% | 11.0% |
| Return on equity | −0.4% | 12.3% |
| Balance sheet | ||
| Net debt | $1.6B | −$556M |
| Net debt / EBITDA | 5.5x | −0.7x |
| Dividends and buybacks | $32.8M | $301M |
| Valuation & quality | ||
| P/E | — | 20.9x |
| Piotroski F-score | 4 | 9 |
Revenue
FY16
BRKR $1.6B
GMED $564M
FY17
BRKR $1.8B
GMED $636M
FY18
BRKR $1.9B
GMED $713M
FY19
BRKR $2.1B
GMED $785M
FY20
BRKR $2.0B
GMED $789M
FY21
BRKR $2.4B
GMED $958M
FY22
BRKR $2.5B
GMED $1.0B
FY23
BRKR $3.0B
GMED $1.6B
FY24
BRKR $3.4B
GMED $2.5B
FY25
BRKR $3.4B
GMED $2.9B
BRKR
GMED
Operating margin
FY16
BRKR 11.3%
GMED 27.3%
FY17
BRKR 12.4%
GMED 25.5%
FY18
BRKR 13.8%
GMED 23.8%
FY19
BRKR 14.5%
GMED 21.9%
FY20
BRKR 12.5%
GMED 14.1%
FY21
BRKR 17.1%
GMED 18.0%
FY22
BRKR 17.1%
GMED 22.3%
FY23
BRKR 14.7%
GMED 8.5%
FY24
BRKR 7.5%
GMED 6.6%
FY25
BRKR 2.0%
GMED 16.3%
BRKR
GMED
Free cash flow
FY16
BRKR $93.7M
GMED $107M
FY17
BRKR $111M
GMED $108M
FY18
BRKR $191M
GMED $122M
FY19
BRKR $140M
GMED $101M
FY20
BRKR $235M
GMED $135M
FY21
BRKR $190M
GMED $219M
FY22
BRKR $145M
GMED $104M
FY23
BRKR $243M
GMED $165M
FY24
BRKR $136M
GMED $405M
FY25
BRKR $43.3M
GMED $589M
BRKR
GMED
Return on capital
FY16
BRKR 21.2%
GMED 14.4%
FY17
BRKR 14.9%
GMED 12.7%
FY18
BRKR 23.8%
GMED 16.6%
FY19
BRKR 21.6%
GMED 14.5%
FY20
BRKR 16.6%
GMED 8.3%
FY21
BRKR 25.1%
GMED 12.0%
FY22
BRKR 21.0%
GMED 13.2%
FY23
BRKR 17.5%
GMED 3.7%
FY24
BRKR 4.8%
GMED 3.7%
FY25
BRKR 0.9%
GMED 11.0%
BRKR
GMED
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.